Silo Pharma is a developmental-stage biopharmaceutical company with no approved products and no product revenue. The company licenses intellectual property from universities — primarily Columbia University — and develops drug candidates targeting neurological and psychiatric conditions including PTSD, chronic pain, Alzheimer's disease, and other CNS disorders. Silo Pharma's lead program, SPC-15, is an intranasal serotonin 4 receptor agonist for PTSD, licensed from Columbia University and delivered via a licensed soft mist nasal spray technology; the company completed a pre-IND meeting with the FDA in 2024 and targets an IND submission in 2026. Other pipeline candidates include SP-26, a subcutaneous ketamine-releasing implant for chronic pain and fibromyalgia, and SPC-14, an intranasal Alzheimer's compound also licensed from Columbia. A fourth program targeting multiple sclerosis appears to be winding down. Silo Pharma's strategy centers on the 505(b)(2) FDA regulatory pathway, which allows the company to rely on existing safety data to potentially reduce clinical development costs. The company's long-term model, if any candidate reaches approval, would involve commercializing university-licensed drugs while paying royalties back to the originating institutions. In 2025, Silo Pharma also added a cryptocurrency treasury strategy, holding Bitcoin, Ethereum, and Solana and staking some assets for yield, though this remains a very small position. The company currently funds operations through capital markets activity and generates minimal revenue from a single licensing arrangement.